The discovery of the RNA programmable nucleases Cas9 and Cpf1 has greatly facilitated genome editing. The impact of CRISPR technology has been universal, bringing drug discovery to an era of whole genome knockout screens and widely distributed multiplexed in vivo gene editing experiments, as well as moving into the clinic to join ZFN and TALEN powered therapies progressing towards registration.

This unique meeting, being held in Dublin, will bring leaders in the field of gene editing together with a wide academic and commercial audience, to explore the new horizons in drug development and therapeutics brought by advancements in CRISPR technology.